{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:26:29Z","timestamp":1789424789354,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Some individuals with spinal muscular atrophy (SMA) transition from nusinersen to risdiplam during disease-modifying therapy (DMT) due to factors such as treatment convenience, economic considerations, and adverse events (AEs). This study evaluates the safety and effectiveness of switching DMTs by analyzing real-world clinical data from multiple centers in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with 5q-SMA who switched from nusinersen to risdiplam were enrolled from four medical institutions in Jiangsu Province. The reasons for switch, as well as any adverse events experienced, were documented. Assessments of motor function were conducted prior to treatment, following the switch, and at four-month intervals subsequently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of eleven patients were included in this retrospective analysis. RULM scores showed maintains improvement following the switch compared to baseline measurements prior to treatment initiation. No significant adverse events were reported after the switch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the small sample size and lack of a control group, these findings suggest that switching from nusinersen to risdiplam in real-world clinical settings is safe and allows for continued improvement of motor function in SMA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1679549","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:19:10Z","timestamp":1769411950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of risdiplam after nusinersen continuously improves upper limb motor function in spinal muscular atrophy patients: a multicenter experience"],"prefix":"10.3389","volume":"14","author":[{"given":"Xi","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Geriatrics, The First Affiliated Hospital with Nanjing Medical University, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Soochow University, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Bei","family":"Fan","sequence":"additional","affiliation":[{"name":"Center of Rehabilitation Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Bing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuzhou Central Hospital","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Rare Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1007\/s00415-024-12318-z","article-title":"JEWELFISH: 24-month results from an open-label study in non-treatment-naive patients with SMA receiving treatment with risdiplam","volume":"271","author":"Chiriboga","year":"2024","journal-title":"J Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-Treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jpc.14959","article-title":"Acknowledging limits: statistics and the child\u2019s quality of life in spinal muscular atrophy","volume":"56","author":"Benini","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mus.28015","article-title":"A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy","volume":"69","author":"Powell","year":"2024","journal-title":"Muscle Nerve"},{"key":"B11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1055\/s-0040-1718916","article-title":"Intrathecal administration of nusinersen in pediatric SMA patients with and without spine deformities: experiences and challenges over 3 years in a single center","volume":"52","author":"Johannsen","year":"2021","journal-title":"Neuropediatrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bcp.70145","article-title":"Switching disease-modifying therapies in patients with spinal muscular atrophy: a systematic review on effectiveness outcomes","author":"Belancic","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/mus.28228","article-title":"Safety of risdiplam in spinal muscular atrophy patients after short-term treatment with nusinersen","volume":"70","author":"Yan","year":"2024","journal-title":"Muscle Nerve"},{"key":"B14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3233\/JND-230096","article-title":"A mixed-method approach to develop an ambulatory module of the SMA independence scale","volume":"10","author":"Staunton","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"120059","DOI":"10.1016\/j.jns.2021.120059","article-title":"Development of the SMA independence scale-upper limb module (SMAIS-ULM): a novel scale for individuals with type 2 and non-ambulant type 3 SMA","volume":"432","author":"Trundell","year":"2022","journal-title":"J Neurol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.3390\/jcm14093173","article-title":"Post-Marketing safety of spinal muscular atrophy therapies: analysis of spontaneous adverse drug reactions from EudraVigilance","volume":"14","author":"Belancic","year":"2025","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1756286418803246","DOI":"10.1177\/1756286418803246","article-title":"Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","author":"Stolte","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/mus.28329","article-title":"Transitioning from nusinersen to risdiplam for spinal muscular atrophy in clinical practice: a single-center experience","volume":"71","author":"Bekircan-Kurt","year":"2025","journal-title":"Muscle Nerve"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1007\/s00415-021-10569-8","article-title":"Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters","volume":"268","author":"Stolte","year":"2021","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/jpm14030244","article-title":"Switching from nusinersen to risdiplam: a Croatian real-world experience on effectiveness and safety","volume":"14","author":"Belancic","year":"2024","journal-title":"J Pers Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0298609","DOI":"10.1371\/journal.pone.0298609","article-title":"Exploration of adverse events associated with risdiplam use: retrospective cases from the US food and drug administration adverse event reporting system (FAERS) database","volume":"19","author":"Yu","year":"2024","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e3630","DOI":"10.1002\/brb3.3630","article-title":"Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China","volume":"14","author":"Li","year":"2024","journal-title":"Brain Behav"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1679549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:11:42Z","timestamp":1771924302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1679549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":24,"alternative-id":["10.3389\/fped.2026.1679549"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1679549","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1679549"}}